vasopressin analogue
Desmopressin updates
Answer
25 changes for Desmopressin in the last 12 months. Latest: 2026-10-02.
| Date | Type | What changed | Source |
|---|---|---|---|
| 2026-10-02 | Trial | New trial registered: FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps | Trial register ClinicalTrials.gov |
| 2026-09-25 | Trial | New trial registered: Prophylactic Desmopressin Before Native Kidney Biopsy in Severe Renal Impairment | Trial register ClinicalTrials.gov |
| 2026-09-16 | Shortage | FDA shortage status current: Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0) | Regulator FDA drug shortages |
| 2026-08-27 | Label | FDA label revised: Desmopressin Acetate (ANDA210223) | Regulator FDA drug label register |
| 2026-08-20 | Trial | New trial registered: Bedtime Device Restriction and Desmopressin in PMNE. | Trial register ClinicalTrials.gov |
| 2026-07-22 | Label | FDA label revised: Stimate (NDA020355) | Regulator FDA drug label register |
| 2026-07-17 | Trial | New trial registered: Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors | Trial register ClinicalTrials.gov |
| 2026-06-22 | Label | FDA label revised: Desmopressin Acetate (ANDA219981) | Regulator FDA drug label register |
| 2026-06-19 | Label | FDA label revised: Desmopressin Acetate (ANDA219981) | Regulator FDA drug label register |
| 2026-05-04 | Trial | New trial registered: International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination | Trial register ClinicalTrials.gov |
| 2026-05-01 | Shortage | FDA shortage status current: Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00) | Regulator FDA drug shortages |
| 2026-05-01 | Shortage | FDA shortage status current: Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0) | Regulator FDA drug shortages |
| 2026-05-01 | Shortage | FDA shortage status current: Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05) | Regulator FDA drug shortages |
| 2026-04-23 | Label | FDA label revised: Desmopressin Acetate (ANDA213095) | Regulator FDA drug label register |
| 2026-04-22 | Recall | FDA recall, Class II: Apotex Corp.. Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners. | Regulator FDA enforcement reports |
| 2026-03-16 | Label | FDA label revised: Desmopressin Acetate (ANDA219981) | Regulator FDA drug label register |
| 2026-03-02 | Label | FDA label revised: DESMODA (NDA219873) | Regulator FDA drug label register |
| 2026-01-23 | Label | FDA label revised: Desmopressin acetate (ANDA074888) | Regulator FDA drug label register |
| 2026-01-01 | Label | FDA label revised: Desmopressin Acetate (ANDA210371) | Regulator FDA drug label register |
| 2025-12-18 | Trial | New trial registered: Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency | Trial register ClinicalTrials.gov |
| 2025-12-05 | Federal Register | Federal Register notice: Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Regulator Federal Register |
| 2025-11-13 | Label | FDA label revised: Desmopressin Acetate (ANDA077414) | Regulator FDA drug label register |
| 2025-11-07 | Label | FDA label revised: Desmopressin Acetate (ANDA077414) | Regulator FDA drug label register |
| 2025-10-24 | Label | FDA label revised: Desmopressin Acetate (NDA018938) | Regulator FDA drug label register |
| 2025-10-23 | Label | FDA label revised: Desmopressin Acetate (NDA018938) | Regulator FDA drug label register |
| 2025-09-30 | Trial | New trial registered: Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE | Trial register ClinicalTrials.gov |
| 2025-09-18 | Trial | New trial registered: DDAVP Effect by TEG6 in Cardiac Surgery | Trial register ClinicalTrials.gov |
| 2025-09-17 | Label | FDA label listed: Desmopressin Acetate | Company says FDA drug label register |
| 2025-08-22 | Label | FDA label listed: DESMOPRESSIN ACETATE | Company says FDA drug label register |
| 2025-07-23 | Label | FDA label revised: Desmopressin Acetate (NDA018938) | Regulator FDA drug label register |
| 2025-06-19 | Label | FDA label revised: Desmopressin Acetate (ANDA074830) | Regulator FDA drug label register |
| 2025-06-19 | Trial | New trial registered: Uroflowmetry and Nocturnal Enuresis | Trial register ClinicalTrials.gov |
| 2025-06-10 | Trial | New trial registered: Transfusion Reduction in High-Bleeding-Risk Cardiac Surgery With Desmopressin | Trial register ClinicalTrials.gov |
| 2025-05-08 | Trial | New trial registered: Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT | Trial register ClinicalTrials.gov |
| 2025-03-19 | Trial | New trial registered: Effectiveness of Pelvic Floor Muscle Rehabilitation Combined With Desmopressin in Children With Primary Monosymptomatic Nocturnal Enuresis | Trial register ClinicalTrials.gov |
| 2025-02-19 | Label | FDA label revised: DESMOPRESSIN ACETATE (ANDA210223) | Regulator FDA drug label register |
| 2025-01-31 | Label | FDA label revised: Desmopressin Acetate (NDA019955) | Regulator FDA drug label register |
| 2025-01-13 | Trial | New trial registered: Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis | Trial register ClinicalTrials.gov |
| 2025-01-13 | Trial | New trial registered: Ginko Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis | Trial register ClinicalTrials.gov |
| 2024-12-06 | Label | FDA label revised: Desmopressin Acetate (NDA019955) | Regulator FDA drug label register |
| 2024-11-19 | Federal Register | Federal Register notice: Pfizer, Inc., et al.; Withdrawal of Approval of 26 New Drug Applications | Regulator Federal Register |
| 2024-10-31 | Federal Register | Federal Register notice: Product-Specific Guidances; Revised Draft Guidances for Industry; Availability | Regulator Federal Register |
| 2024-10-10 | Trial | New trial registered: Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome | Trial register ClinicalTrials.gov |
| 2024-10-02 | Trial | New trial registered: Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies | Trial register ClinicalTrials.gov |
| 2024-09-27 | Label | FDA label revised: DESMOPRESSIN ACETATE (ANDA210218) | Regulator FDA drug label register |
| 2024-06-03 | Federal Register | Federal Register notice: Pfizer, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications | Regulator Federal Register |
| 2024-05-07 | Results | Results posted: Desmopressin for Bedwetting in Children With SCD | Trial register ClinicalTrials.gov |
| 2024-03-29 | Trial | New trial registered: Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial | Trial register ClinicalTrials.gov |
| 2024-03-25 | Label | FDA label revised: Desmopressin Acetate (ANDA213095) | Regulator FDA drug label register |
| 2024-03-22 | Label | FDA label revised: Desmopressin Acetate (ANDA210223) | Regulator FDA drug label register |
| 2024-03-18 | Results | Results posted: A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers | Trial register ClinicalTrials.gov |
| 2024-02-29 | Trial | New trial registered: Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis | Trial register ClinicalTrials.gov |
| 2024-02-21 | Label | FDA label revised: Desmopressin Acetate (ANDA210371) | Regulator FDA drug label register |
| 2024-02-13 | Trial | New trial registered: Analysis of the Clinical Efficacy of Intravenous Application of Hemostatic Drugs in Improving the Clarity of Vision Under Endoscope, Perioperative B | Trial register ClinicalTrials.gov |
| 2024-01-30 | Trial | New trial registered: Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD | Trial register ClinicalTrials.gov |
| 2024-01-15 | Label | FDA label revised: Desmopressin Acetate (ANDA210223) | Regulator FDA drug label register |
| 2023-12-29 | Trial | New trial registered: Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis. | Trial register ClinicalTrials.gov |
| 2023-09-06 | Label | FDA label revised: Desmopressin Acetate (ANDA216922) | Regulator FDA drug label register |
| 2023-09-06 | Label | FDA label revised: Desmopressin Acetate (ANDA216904) | Regulator FDA drug label register |
| 2023-08-31 | Trial | New trial registered: Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A | Trial register ClinicalTrials.gov |
| 2023-08-28 | Trial | New trial registered: Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia | Trial register ClinicalTrials.gov |
| 2023-08-16 | Results | Results posted: DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty | Trial register ClinicalTrials.gov |
| 2023-08-04 | Label | FDA label revised: Desmopressin Acetate (ANDA077414) | Regulator FDA drug label register |
| 2023-07-14 | Trial | New trial registered: Adding Desmopressin to Tamsulosin for Treatment of BPH | Trial register ClinicalTrials.gov |
| 2023-06-06 | Label | FDA label revised: Desmopressin Acetate (ANDA216904) | Regulator FDA drug label register |
| 2023-04-06 | Label | FDA label revised: Desmopressin Acetate (ANDA216922) | Regulator FDA drug label register |
| 2023-03-23 | Label | FDA label revised: Desmopressin Acetate (ANDA216904) | Regulator FDA drug label register |
| 2023-02-06 | Federal Register | Federal Register notice: Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn F | Regulator Federal Register |
| 2022-12-14 | Recall | FDA recall, Class II: RemedyRepack Inc.. Subpotent Drug: repackaged product was recalled by the manufacturer for subpotency. | Regulator FDA enforcement reports |
| 2022-12-07 | Recall | FDA recall, Class II: Heritage Pharmaceuticals Inc. Subpotent Drug | Regulator FDA enforcement reports |
| 2022-11-28 | Trial | New trial registered: Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A | Trial register ClinicalTrials.gov |
| 2022-11-18 | Label | FDA label revised: Desmopressin Acetate (ANDA216922) | Regulator FDA drug label register |
| 2022-11-15 | Trial | New trial registered: Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis | Trial register ClinicalTrials.gov |
| 2022-10-12 | Label | FDA label revised: desmopressin acetate (ANDA204695) | Regulator FDA drug label register |
| 2022-10-12 | Label | FDA label revised: desmopressin acetate (ANDA204751) | Regulator FDA drug label register |
| 2022-09-28 | Label | FDA label revised: DDAVP (NDA018938) | Regulator FDA drug label register |
| 2022-08-26 | Trial | New trial registered: Intravenous Tranexamic Acid and Intramyometrial Desmopressin Effect on Blood Loss During Laparoscopic Myomectomy. | Trial register ClinicalTrials.gov |
| 2022-08-24 | Label | FDA label revised: Desmopressin Acetate (ANDA091280) | Regulator FDA drug label register |
| 2022-08-19 | Trial | New trial registered: Nasal Desmopressin Versus Topical Epinephrine in Endonasal Dacryocystorhinostomy | Trial register ClinicalTrials.gov |
| 2022-07-26 | Label | FDA label revised: Desmopressin Acetate (ANDA215961) | Regulator FDA drug label register |
| 2022-07-20 | Trial | New trial registered: Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin | Trial register ClinicalTrials.gov |
| 2022-07-06 | Recall | FDA recall, Class II: Glenmark Pharmaceuticals Inc., USA. CGMP Deviations | Regulator FDA enforcement reports |
| 2022-06-24 | Trial | New trial registered: Nasal Desmopressin Versus Oral Bisoprolol for Controlling Bleeding During Endoscopic Sinus Surgery | Trial register ClinicalTrials.gov |
| 2022-06-07 | Trial | New trial registered: Validation of Capillary Serum Sodium Levels | Trial register ClinicalTrials.gov |
| 2022-06-01 | Trial | New trial registered: Effect of Laser Acupuncture for Treating Monosymptomatic Nocturnal Enuresis in Adolescent Females | Trial register ClinicalTrials.gov |
| 2022-04-01 | Trial | New trial registered: Decline in Renal Concentration Ability in Lithium Treated Patients | Trial register ClinicalTrials.gov |
| 2022-03-30 | Label | FDA label revised: Desmopressin Acetate (ANDA207880) | Regulator FDA drug label register |
| 2021-11-18 | Federal Register | Federal Register notice: Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications | Regulator Federal Register |
| 2021-09-01 | Label | FDA label revised: Desmopressin Acetate (ANDA074830) | Regulator FDA drug label register |
| 2021-03-03 | Recall | FDA recall, Class II: Teva Pharmaceuticals USA. Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial rec | Regulator FDA enforcement reports |
| 2021-02-03 | Label | FDA label revised: DDAVP (NDA019955) | Regulator FDA drug label register |
| 2021-01-29 | Trial | New trial registered: NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden | Trial register ClinicalTrials.gov |
| 2021-01-20 | Results | Results posted: Long Term Safety Assessment of SER120 in Patients With Nocturia | Trial register ClinicalTrials.gov |
| 2020-12-23 | Results | Results posted: A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults | Trial register ClinicalTrials.gov |
| 2020-10-07 | Trial | New trial registered: the Effect of Oral Vasopressors for Liberation From IV Vasopressors in Spinal Shock | Trial register ClinicalTrials.gov |
| 2020-09-30 | Trial | New trial registered: DDAVP for Pituitary Adenoma | Trial register ClinicalTrials.gov |
| 2020-09-11 | Trial | New trial registered: Posterior Tibial Nerve Stimulation Vs Desmopressin In Children With Primary Monosymptomatic Nocturnal Enuresis | Trial register ClinicalTrials.gov |
| 2020-08-26 | Recall | FDA recall, Class I: Ferring Pharmaceuticals Inc. Superpotent Drug | Regulator FDA enforcement reports |
| 2020-08-26 | Recall | FDA recall, Class I: Ferring Pharmaceuticals Inc. Superpotent Drug | Regulator FDA enforcement reports |
| 2020-08-26 | Recall | FDA recall, Class I: Ferring Pharmaceuticals Inc. Superpotent Drug | Regulator FDA enforcement reports |
The 100 newest of 224 are listed.
From ClinicalTrials.gov, EU CTIS, FDA labels, recalls, shortages and warning letters, the Federal Register, and regulators' published actions. Not medical advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.